From original filings
to an investable thesis.

• At the stored USD 14.29 common quote, the share trades at 7.56 x our forward AFFO per fully diluted unit. Base AFFO of USD 40.5 m is slightly below the USD 40.704 m H1 annualized run-rate; no full vacant-property recovery is assumed.
• The latest USD 0.43 quarterly declaration supports an assumed USD 1.72 over four future quarters only if maintained. The USD 16.00 target implies 11.97% capital upside; adding those assumed dividends gives 24.00% modeled total return. The two measures remain separate.
• June gross debt of USD 7.6 m and cash of USD 25.762 m provide capacity for the disclosed USD 2.2 m Kentucky purchase/improvement commitment. These are dated balances, not a claim about current cash.
• The base 8.5 x equity AFFO multiple is a CIN judgment that discounts tenant credit, empty properties and OTC liquidity. It is not external analyst consensus or a measured peer median.

Cannabis exposure: Internally managed triple-net landlord to state-licensed cannabis operators.

Selected 12-month target: USD 16.00. CIN selectsUSD16.00 below computedUSD16.0573308, rounded conservatively downward.

Reference quote USD 14.29 dated 2026-10-23T19:56:00Z; retained native market observation, not independently certified exchange close. Price return 11.97%; modeled total return 24.00% including assumed dividends. No return is guaranteed.

Capital and claim bridge

20.580766 m common +0.357380 m LPI +0.104015 m vested RSUs +0.075203 m unvested RSUs +0.221442 m maximum existing PSUs +0.100000 m CIN future-award allowance =21.438806 m economic units. USD 24 options/warrants expire July 2027, are out of money in every scenario, and contribute no proceeds. Levered AFFO includes LPI economics: no second NCI or debt subtraction. June cash 25.762 m and debt 7.6 m are dated; known Kentucky price/improvement commitment 2.2 m does not establish current cash.

Forecast discipline

• Forward AFFO, multiples, dividends and future awards are CIN judgments, not issuer guidance.
• Base USD 40.5 m broadly maintains the USD 40.704 m H1 annualized AFFO run-rate: escalators/Kentucky returns offset tenant pressure and costs. Bear USD 34 m admits collection losses and carry costs; bull USD 45 m requires improved leasing/tenant stability.
• Base 8.5 x versus bear 6.5 x and bull 10 x are selected risk multiples; no claim of peer-median precision.
• Rating policy uses modeled total return: Buy at or above 15%; Sell at or below minus 15%; Hold between. Dividends are excluded from capital-price upside.
• Four future USD 0.43 dividends are assumed in base/bull, not guaranteed. Bear cuts annual dividends to USD 1.30. The prior declaration does not authorize a future payment.

Risks and what would change CIN’s view

• Cannabist entered Canadian CCAA proceedings, recognized under US Chapter 15. Four properties were current through Q2; that does not establish future collection. The source describes the July Vireo sale agreement as conditional.
• Three vacant cultivation facilities reduced revenue and AFFO. Specialized properties can require carrying costs, further capital and long re-leasing periods.
• Full Q2 contractual rent collection is not full occupancy or a guarantee of tenant solvency. Other cannabis tenants also face financing and margin pressures.
• At maximum modeled dilution, assumed dividends consume 91.05% of base AFFO. A dividend reduction is credible; bear assumes USD 1.30 annual distribution instead of USD 1.72.
• AFFO adds back stock compensation and is not free cash flow. Known awards are included in dilution; future financing or improvement spending can exceed the allowances.
• One bank supplies the USD 90 m revolver. Borrowing above USD 30 m requires approval; the amended interest floor is 6.25%.
• The bounded issuer news/filing review is not a complete corporate-actions feed. A new Q3 share count, tenant event or capital action requires immediate reassessment. The stored quote is not independently certified as the official close.

• Quarterly AFFO per modeled diluted unit below USD 0.42 without a credible temporary explanation.
• A rent default or impairment invalidating base USD 40.5 m AFFO.
• Unexpected common dilution above 3%, or a large unfunded capital commitment.
• Dividend reduction or new Q3 cash evidence undermining the distribution run-rate.

Next evidence window

• November 5 scheduled Q3 results: rent collection, occupancy, capital spending and share count.
• Documented re-leasing of vacant cultivation facilities.
• Actual Cannabist/Vireo transaction completion and lease assumption, rather than announcement alone.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• The stored USD 3.01 price is only 36.5% of reported June NAV. A steep discount is warranted. CIN selects USD 4.00 after additional USD 15 m credit losses beyond existing marks, refinancing costs, remaining buyback reserve and a prudent RIC distribution outflow reserve.
• The original portfolio is already marked USD 64.56 m below cost. Subtracting that historical discount again would double count losses; our incremental stress is applied beyond June fair value.
• The BDC transition is real: this is no longer a cannabis-only mortgage REIT. Cannabis still represents about 68.47% of investment fair value, so the legacy credit problem remains material.
• Base annual NII of USD 12 m is below the USD 13.93 m Q2 annualized run-rate. At least 90% of modeled NII is reserved as an outflow in the NAV model where that exceeds the assumed declared dividend rate; this does not invent taxable income or promise those distributions.

Cannabis exposure: Converted from REIT to externally managed BDC effective January 1,2026. Cannabis remains USD 198.410636 m of USD 289.763599 m investment fair value (68.47%), with cross-industry credit now included.

Selected 12-month target: USD 4.00. CIN conservatively selects USD 4.00 below the USD 4.10141 base target-date model value; scenario sensitivities are rounded to nearest 0.10.

Reference quote USD 3.01 dated 2026-10-23T20:00:00Z; retained native market observation, not independently certified exchange close. Price return 32.89%; modeled total return 39.53% including assumed dividends. No return is guaranteed.

Capital and claim bridge

June assets 399.718181 m less liabilities 212.448681 m less unamortized debt discount 0.424664 m =186.844836 m face-adjusted net assets. July 1 debt repayment 104.4 m consumes equal cash, leaving net debt unchanged; June 106.508623 m cash is not excess current liquidity. Use conservative June 22.689438 m shares, above August 7 count 22.671919 m, plus full 2.225443 m remaining buyback cash reserve without share-count credit. Existing debt/NCI liabilities are not subtracted twice. The September 130 m revolver increase was temporary; normal 80 m remains borrowing-base dependent.

NAV reserves the higher of declared-rate cash and 90% modeledNII across 480 days. This prudential outflow is neither a tax calculation nor a declared dividend; investor return credits only 0.20 USD assumed dividends.

Forecast discipline

• Base USD 12 m annual NII includes all interest, fees and taxes, including the higher cost of refinancing 77 m notes; it is not cash income alone. No additional management guidance is invented.
• Incremental losses are 75/15/0 m in bear/base/bull on top of the existing 64.56 m cost-to-FV discount; no historical loss is deducted twice.
• Base refinancing fee 2 m is a CIN assumption, not a signed transaction; maturity must be resolved. The 77 m principal is replaced or funded at par, not deducted again from NAV.
• Base dividend 0.20 is four assumed 0.05 quarters; bear 0.10. These future distributions are not guaranteed.
• CIN P/NAV multiples 35/55/75% represent uncertainty discounts, not observed industry medians.
• NAV income/dividend bridge covers 480 days from June 30,2026 to October 23,2027. Incremental credit losses and refinancing costs are cumulative one-off stresses over that full period, not annualized. The 12-month investor total return counts only the next 12 months assumed dividends.
• Target USD 4.00 implies 32.89% capital upside. Only assumed USD 0.20 next-twelve-month dividends are added for 39.53% expected total return; the higher tax/distribution reserve is not a promised investor cash receipt.
• No favorable taxable-income/NOL bridge is established. A cash outflow reserve of at least 90% modeled GAAP NII is used prudentially, and actual tax-driven needs could be higher. The reserve reduces forward NAV independently of the lower dividend credited to investor returns.

Risks and what would change CIN’s view

• Three nonaccrual borrowers represent USD 65.9 m at fair value,22.7% of debt investments. Collateral realizations can miss management marks; all major positions are illiquid and model-valued.
• USD 77 m notes mature in May 2027, inside the target horizon. Base assumes refinancing with USD 2 m costs and higher interest within NII; refinancing is not secured by this model. Failure can cause forced sales and invalidate Buy.
• June USD 106.5 m cash was not excess distributable cash: USD 104.4 m debt was repaid July 1. The September temporary borrowing accommodation ended October 20; permanent 80 m availability remains subject to borrowing-base conditions.
• Q2 PIK income was USD 0.783 m. NII is not entirely cash and BDC operating cash flow includes investment purchases; a simple industrial-company free-cash-flow multiple is unsuitable.
• AFC intends RIC tax treatment and generally must distribute 90% of investment-company taxable income. GAAP NII is not the same tax measure. Actual required distributions, gains or taxes may exceed the modeled reserve. Externally managed fees and affiliate conflicts can impair returns.
• Base P/NAV55% is a CIN opinion, not a peer median or liquidation guarantee. Additional 75 m bear credit loss and 35% multiple produce aboutUSD1.64 after the prudent distribution reserve.
• The latest original share count is August 7, not October 23. The conservative denominator/cash reserve does not protect against a new large common issue or unreported new loss.

• No credible funded plan for May 2027 note maturity before year-end 2026.
• New credit losses materially exceed the 15 m base incremental stress.
• Asset coverage, loan borrowing-base constraints or new dilution materially change the equity bridge.
• Annualized NII materially below 12 m, or noncash income makes dividend coverage unreliable.

Next evidence window

• Next original Q3 report, including subsequent debt balances, portfolio marks, nonaccruals and share count.
• A documented plan and completed financing for May 2027 notes.
• Actual Devi collateral-sale proceeds and net creditor recovery; the source July 12.5 m term sheet was conditional and shared, not full AFC recovery.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• Cannabis credit income and the latest USD 0.47 quarterly declaration support an income case, but June distributable earnings of USD 0.43 per diluted share did not fully cover the dividend. The subsequent share issuance changes per-share economics.
• The July Koach transaction was not cash financing:4,306,754 common shares were exchanged for approximately USD 62.5 m second-lien notes. ASC505 presents the notes as an equity reduction, while merger NAV treats them as assets.
• June book value of USD 14.15 per share cannot be carried forward unchanged after the July issuance and different merger valuation rules. Q2 interest income actually fell from USD 16.502 m to USD 15.219 m, rather than rising.
• The eventual holding may be LIEN rather than REFI. Closing REFI NAV per share divided by closing LIEN NAV per share sets the floating exchange ratio; it is not fixed by the historical accounts.

Why a current target is withheld

Pending affiliated LIEN merger with a NAV-based floating exchange ratio, changed share count and different GAAP/economic treatment of Koach notes. The surviving-security price, closing ratio and transaction-cost/capital bridge are not established; standalone conditional sensitivities are not twelve-month targets.

Downside and next tests

• Related-party loans, nonaccruals and collateral values can change the closing NAV. The separate Note 8 loan 9 exposure must not be omitted by counting only two other nonaccrual loans.
• Koach notes are second-lien obligations with 10%cash,2%PIK, contingent exit economics and roughly 12 year life; face value is not guaranteed realizable value.
• The affiliated merger requires approvals, effectiveness of registration materials and closing valuations. Termination is permitted if not completed by June 30,2027 under specified terms.
• The changed common denominator and treatment of the Koach notes can materially affect dividend coverage, GAAP NAV and merger NAV differently.
• The prior declaration of 1.88 annualized distributions is not a guaranteed forward return; merger distribution policy can change.

• November 10 scheduled Q3 results: updated shares, loans and dividend coverage.
• Effective merger registration/proxy, voting results and current LIEN security/NAV evidence.
• Actual closing NAV certificate, exchange ratio and transaction expenses.

CIN model assumptions

• Conditional scenarios use CIN recovery fractions, incremental credit losses, earnings and discounts; they are not targets or current-NAV certifications.
• The 26.221146 m conditional denominator is Aug 6 common plus 0.6 m uncertainty allowance. It does not certify all current dilution.
• Koach recovery is added for economic sensitivity, not relabelled a recognized GAAP asset or cash.
• No current LIEN market price, exact closing NAV ratio, transaction-expense bridge or confirmed completion is supplied in the reviewed source set.
• Economic sensitivities span 480 days from June 30,2026 to October 23,2027, not an abbreviated twelve-month rollforward from the old balance sheet. They still do not resolve merger consideration.

Model limits

• No qualified CIN price target or upside is issued. Numerical conditional values are standalone sensitivities and omit merger conversion.
• The source index is a bounded current window, not exhaustive absence-of-event proof.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

CIN sees approximately fair value at the dated reference quote. Lawn-and-garden margin recovery supports earnings, but at 13 x CIN tax-normalized fiscal 2027 EPS there is little capital appreciation in the base case. The declared dividend run-rate improves modeled return without eliminating financing and seasonal risk. This is a Hold research opinion, not a portfolio sizing instruction.

Cannabis exposure: Hawthorne North America was divested April 8,2026. SMG is primarily lawn and garden; retained Vireo investment exposure is indirect. Do not count all SMG group sales as cannabis-market revenue.

Selected 12-month target: USD 58.50. Base EPS×multiple, rounded to cents.

Reference quote USD 59.29 dated 2026-10-23T20:11:00.000Z; retained native market observation, not independently certified exchange close. Price return -1.33%; modeled total return 3.12% including assumed dividends. No return is guaranteed.

Capital and claim bridge

Q3 diluted weighted denominator 59.2 m already includes potential dilution in reported EPS. The model grants no future share-count reduction: AugustUSD25 m repurchases are acknowledged but no unknown execution price/share reduction is invented. SeptemberUSD250 m note redemption used both revolver and free cash flow; it is not treated asUSD250 m net deleveraging. Black Kow consideration is undisclosed and October closing remains unverified: no extra accretion is capitalized. September 15 reaffirmation followed that announcement. No separate Vireo equity/warrant value is added, avoiding double counting investment marks already excluded from normalized earnings.

Forecast discipline

FY2026 guidance midpoint 4.375 × CIN1.05 pretax/share growth × (1−0.29)/(1−0.275)=4.498707≈4.50 FY2027 EPS. FY2027 tax 29% versus FY2026 midpoint 27.5% is a conservative CIN normalization assumption; no future share repurchases are credited. Management’s 2027–2029 average EPS-growth aspiration is 5–8%, not a specific FY2027 promise.13 x is CIN judgment: a modest growth franchise discounted for leverage/seasonality; it is not a claimed peer median.

Use continuing-business earnings; exclude Hawthorne operating earnings after April 8 divestiture. Q3 GAAP continuing EPS1.75 reconciles to adjusted 2.82; this earnings measure excludes specified restructuring/impairments and investment marks and is not GAAP or cash earnings. Stock compensation is not added back separately in this model. Bear EPS4.00 tests a miss below current management range; bull 5.00 requires stronger execution.

Risks and what would change CIN’s view

• A seasonal/weather or retailer-inventory miss cuts earnings while high leverage persists.
• Adjusted EPS excludes real restructuring and investment losses; cash conversion can lag EPS.
• Black Kow purchase terms and post-close capital effects remain undisclosed; adverse terms would invalidate the forecast.
• Management’s multi-year algorithm may not be achieved; the 13 x multiple is CIN judgment, not market consensus.

• FY2026 adjusted continuing EPS belowUSD4.30 or a FY2027 outlook inconsistent withUSD4.50.
• Failure to sustain cash flow/deleveraging or new material financing/dilution not incorporated here.
• A material Black Kow funding obligation, share action or renewed discontinued-business cost invalidates normalized EPS.

Next evidence window

• Fiscal 2026 results scheduled November 4,2026; current model expires for re-underwriting then.
• Black Kow closing and purchase-price disclosure; balance-sheet and earnings effects require a new model when material.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

The larger modern-oral mix can create growth, but marketing, manufacturing and distribution spending currently consume that growth. A group-sales growth rate does not establish common-share earnings. The stock question is how much recurring attributable cash generation remains after PMTA/regulatory costs, minority economics and compensation; the existing adjusted EBITDA adds back items that may recur. A naive groupEV/EBITDA target would conceal these claims.

Why a current target is withheld

• No supported forward attributable earnings/PMTA/SBC and minority-claim bridge yet; conditional EPS are sensitivities, not estimates or targets.
• Post-July ATM execution and current capital roll-forward have not been verified.
• Cannabis exposure is ancillary Zig-Zag, while nicotine/tobacco dominates; do not equate group sales with cannabis sales.

Downside and next tests

• Reconcile recurring group EBITDA to attributable earnings/free cash flow and common dilution.
• Verify later capital actions and latest issuance status from original filings before assigning a current target.
• Watch Zig-Zag contraction versus modern-oral net revenue and unit economics.

Selected original reported evidence

• Q2 salesUSD142.960 m; modern-oral net salesUSD68.4 m versus grossUSD87.0 m.
• Q2 attributable GAAP earningsUSD3.598 m, basic/dilutedEPSUSD0.18; adjustedEPSUSD0.23.
• Q2 adjustedEBITDAUSD15.2 m; FY2026 guidanceUSD70–90 m. Do not annualize the tariff-refund benefit.
• June cashUSD268.307 m and note principalUSD300 m; useUSD31.693 m net financial debt, not all liabilities.
• June/July 28 common 20,048,922; Q2 diluted weighted 20,160,795. ATM672,884 shares raisedUSD59.6 m net inQ2; USD 139.2 m remaining capacity is not issued shares.
• Noncontrolling interest receivesUSD6.703 m of Q2 consolidatedNIUSD10.301 m. Attributable earnings and consolidated enterprise value require different claim bridges.

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

Cash-generating sleep/epilepsy franchises and oncology progress create a credible research case. The investment question is whether earnings durability and launch economics outweigh debt, generic competition and acquired pipeline spending. The October 23 survival update is new clinical evidence, not an automatic probability-adjusted commercial valuation. A multiple of annualized nonGAAPQ2 EPS would skip acquired R&D, amortization, financing and share settlement.

Why a current target is withheld

• Post-August notes/repurchase closing, option exercise, Actio funding and contingent consideration/cash bridge are not fully reconciled.
• Pipeline probabilities, patent/generic erosion, new indications, royalties and recurring R&D must support a forward earnings model.
• CIN has not yet established the normalizedEPS sensitivities as forecasts; no current rating/target or upside is issued.

Downside and next tests

• Reconcile third-quarter accounts after the debt/repurchase/Actio transactions; results are scheduledNovember 2.
• Assess actual new-indication commercial uptake separately from clinical efficacy announcements.
• Build a product-specific forecast and financing/dilution bridge rather than multiplying one adjusted quarter.

Selected original reported evidence

• Q2 revenueUSD1,208.3 m; Epidiolex/EpidyolexUSD292 m. CBD is a pharmaceutical segment, not all group revenue.
• Q2 GAAP dilutedEPSUSD2.78 versus nonGAAPUSD5.71; H1 operatingcashUSD824 m.
• June cash/equivalents/investmentsUSD2.2 bn and principaldebtUSD4.4 bn predate later financing/acquisition.
• August 27 pricedUSD1.1 bn 1.875%notes due 2032, withUSD150 m option and initialUSD355.24 exchange price; closing was expected, not proved by a pricing release.
• ConcurrentUSD225 m repurchases pricedUSD249.29 imply about 0.903 mshares; execution/current denominator still need closing evidence.
• Actio acquisition completedSeptember 15 forUSD820 m upfront. June cash cannot be carried forward unchanged.

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• The operating turnaround is real but thin: the Q2 operating loss was CAD 34,000 and net profit CAD 4,000. A CAD 894,000 adjusted EBITDA headline does not establish recurring free cash flow.
• Germany offset weakness elsewhere, but Q2 group revenue still fell year over year. The investment hinge is sustained international growth with cash conversion after recurring compensation and working capital.
• The balance sheet offers a financing cushion compared with heavily leveraged growers. Do not add the owned production properties to an operating-enterprise valuation: they are already productive assets, and an appraisal is not realizable equity cash.
• Clinical/formulation and new-market optionality is assigned zero separate value in this model until economics, funding and monetization evidence are available.

Why a current target is withheld

No matching TSX CAD quote or dated FX bridge was obtained; the USD MEDIF quote is retained separately. More fundamentally, maintenance reinvestment and sustainable after-working-capital cash conversion remain assumptions, and the latest share/option schedule is only dated Aug 12. The model below is a transparent conditional CAD equity-value framework, not an issued current target.

Downside and next tests

• H1 operating cash outflow persisted and inventories absorbed cash. A stable quarter-end balance is not proof of self-funded growth.
• Adjusted EBITDA excludes share compensation and other items; cash operating margins and maintenance capex must support a target.
• Foreign reimbursement/prescription conditions and customer concentration can reverse the turnaround; this report does not assert current legal permission in any market.
• Options/RSU settlement and withholding can consume shares or cash. No option-exercise proceeds are assumed in the conservative dilution model.
• The Aug 12 MD&A says an appeal was scheduled for Oct 14; the bounded current source check did not establish its subsequent outcome. No CAD 50 m liability is inferred: the issuer reports no provision, and the cited costs proceeding was not against the Company.

• Next quarterly financial disclosure · expected evidence window, not a confirmed announcement date · Positive cash flow after working capital and maintenance spending, not only adjusted EBITDA.
• German/international mix and reimbursement mitigation · operating monitor · Sustained group revenue, margin and cash conversion with original reported dates.
• Post-Oct 14 legal/governance update · outcome unverified · Read any original outcome disclosure; do not recycle the old hearing date as a new catalyst.

CIN model assumptions

• EBITDA retains recurring share-compensation cost; no extra clinical/patent value, property-sale proceeds, financing proceeds or option cash proceeds.
• Multiples 0/6/8 x and operating forecasts are selected CIN judgments, not externally established peer multiples.
• Zero modeled cash tax is an assumption reflecting losses, not verification of usable tax assets.
• Capex and working-capital assumptions need confirmation; an extraCAD1 m reinvestment lowers conditional value byCAD0.002118070896272375 per potential share.

Model limits

• No current CAD upside is calculable from the separate USD quote.
• Forward cash margins and maintenance spending are unproven; no current target is issued.
• No new post-Aug 12 capitalization certificate; verify before issuance.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• Commercial differentiation is not yet financing independence. Higher branded-product mix improved gross margin, while group revenue and cash conversion weakened.
• Canada carries the near-term commercial thesis; Colombia/API assets cannot simply be valued at 100% for parent shareholders. The group consolidates subsidiaries with 49% and 40% outside interests.
• The MyMedi program and QUIX rollout are operating tests, not assumed contracted orders. A durable improvement requires collected revenue, lower overdue payables and positive cash generation.
• A small strategic placement buys financing capacity but is not evidence of a now-funded business plan. The equity case must be valued after the funding and minority-interest bridge.

Why a current target is withheld

Additional financing needs, overdue vendors and November debt maturity are not reconciled to current available cash. A fair minority-interest/SOTP bridge and current dilution schedule are absent. Therefore no per-share target or price-relative rating is supportable despite a same-currency stored quote.

Downside and next tests

• Explicit going-concern material uncertainty in the original statement. Cash and vendor arrears make dilution/creditor accommodation central, even when adjusted EBITDA appears near break-even.
• CAD 4.123 m trade payables were more than 60 days overdue atJun 30. Counting all payables as separate debt as well as forecasting vendor catch-up in working capital would double-count; the model instead leaves the cash bridge unresolved.
• A related-party SMGH loan carries 15% interest and aNov 15,2026 maturity; a future repayment or extension is not assumed completed.
• The book NCI balance is not an appraised outside equity claim. A consolidated EV multiple requires a fair NCI bridge or subsidiary-specific SOTP.
• New share units, warrants and possible further capital must be reconciled afterAug 19; June warrant schedules contain near-expiry tranches and cannot be treated as current fully diluted shares unchanged.

• Loan maturity · 2026-11-15 · Contractual maturity as disclosed in original Q2 note 18; settlement/extension not verified · Funding source, terms and effect on parent/minority economics.
• Next quarterly results / cash and vendor payment update · Unconfirmed reporting window · Cash after financing, collections, overdue-payable reduction and funded 12-month plan.
• QUIX/MyMedi commercialization · Announced company initiative · Collected revenue and repeat patient/order economics, not listings alone.

CIN model assumptions

• All revenue, margin and multiples are CIN judgments, not company guidance or broker estimates.
• BearEVfloorzero is a stress convention, not an asset recovery appraisal.
• No proprietary clinical/patent optionality is assigned a fabricated value.

Model limits

• The original Q2 MD&A link returned an HTML response, not a financial PDF; only the actual statement and issuer releases were verified.
• Reported current loan inflow appears within the operating working-capital table; an economic cash-burn review should distinguish that funding rather than treat it as recurring operating collection.
• The company site retains a historicMCTObanner; it is not treated as a newOct 2026 cease-trade event.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• The premium-brand expansion is converting into reported revenue, but the cash return on the enlarged production base remains unproven. The next useful test is gross profit and cash after the Cascadia/lighting ramp, not capacity alone.
• Q2 adjusted EBITDA excludes more startup cost than the reported EBITDA itself. Retaining that cash operating cost and recurring share compensation leaves negative economic EBITDA; a four-times quarterly headline is an unsuitable base earnings assumption.
• The Oct 19 financing is real new equity, not debt, but proceeds are principally intended for lighting and expansion. Adding the fullCAD3 m to valuation cash while omitting the associated spend would overstate shareholder value.
• A properly matched Canadian stored quote exists. A target still requires a current definition- and date-matched share/award bridge and a funded forward cash-return model; different denominator definitions are not treated as an accounting error.

Why a current target is withheld

A full current, definition- and date-matched dilution/claims bridge and a funded forward cash-return model are not yet established. The common-plus-DSU count nearly aligns with weighted-basic EPS units, and the PSU disclosures have different dates; neither is asserted to be a source contradiction. Ramp-up economics, capex/working-capital needs and final exchange acceptance remain explicit checks. Therefore no current shareholder target is issued from selected EBITDA multiples alone.

Downside and next tests

• The June 30 common-share count of 67,578,916 plus 2,991,268 DSUs equals 70,570,184, almost identical to 70,570,186 reported Q2 weighted-basic shares. This numerical alignment suggests a denominator-definition difference; the exact EPS policy was not verified, so no source contradiction or accounting error is asserted. Weighted-average EPS units are not automatically current outstanding common shares.
• The financial statement lists 1,670,543 PSUs atJune 30; the MD&A lists 983,757 PSUs and 80,696,276 total potential units atAugust 11. These are different dates and are not a same-period contradiction. A current claims bridge must trace subsequent award movements and theOctober 19 placement rather than combine older and newer award counts.
• H1 operating cash was helped by working-capital timing and remains insufficient for capex, interest and lease outflows. Line-of-credit funding increases near-term refinancing sensitivity.
• Reported net income includes biological fair-value gains; cash margins and operating conversion need separate evaluation.
• The issuer disclosed a paid Atrium research engagement. This does not establish independent market consensus; no outside target is imported or endorsement inferred.

• Lighting upgrade/expanded capacity · 2027-06 · Company forecast, not a confirmed completed project · Saleable production, margins, funding and collected sales; stated 20,000 kg target is not automatically revenue.
• Next quarterly cash and capital disclosure · Unconfirmed reporting window · Reconcile actual common/award counts, gross cash margins and cash after capex/interest/lease payments.
• FinalTSXVplacement acceptance · Stated outstanding condition inOct 19 release · Read actual final acceptance; do not invent completion date.

CIN model assumptions

• Forecasts and 0/6/8 xmultiples are CIN judgment, not consensus or observed peer medians.
• EVstressfloorzero is not liquidation NAV.
• No current per-share target until the date- and definition-matched claims bridge, funded cash conversion and forward operating return are underwritten.

Model limits

• Capacity, product listings and company-reported market share do not establish current orders or transaction permission.
• The originalOct 21 CADquote remainsdated, and the incorrectROMJF/CADquote is not relabeled.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• The payments/POS business has direct cannabis exposure. Q2 total revenue fell while gross profit rose; a higher-margin mix is evidence, not proof of durable cash earnings.
• A substantial portion of reported cash generation comes from collecting a pre-existing license contract asset. The June balance is much lower than December; it must not be valued as a perpetual stream.
• September refinancing improves rate and maturity but accelerates some principal cash needs. A related-party lender and contingent tax-refund prepayment require an explicit liquidity bridge.

Why a current target is withheld

Recurring normalized cash flow and the current gross-debt/payment/dilution bridge are incomplete; a numeric twelve-month target would capitalize a depleting license asset or invent renewal/financing terms.

Downside and next tests

• Core profitability after the old license collections expire is not demonstrated.
• Related-party Perga debt, tax-refund-dependent payment terms and SBA gross principal require full current reconciliation.
• Option/RSU/warrant dilution and USD reporting versus CAD warrant strikes require matching units; deferred RSUs must not be counted twice.

• Next original quarterly statement showing post-license recurring operating cash flow.
• Disclosure of actual Perga payments, tax-refund receipt and complete amended schedule.

CIN model assumptions

• No perpetual capitalization or annualization of old license cash collections.
• No renewal, tax refund, gross SBA balance, FX rate or new equity proceeds invented.

Model limits

• Original loan amendment complete amortization and tax-refund conditionality not captured.
• No current original capital register after June and no verified compatible listing quote basis.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• The fee/loan-program platform has direct cannabis exposure, but deposits belong to clients at partner banks and do not form a cash asset for equity valuation.
• Q2 revenue grew 4.845% year over year while operating and common-attributable losses remain material.
• H1 cash burn, preferred/redemption economics and ongoing ELOC share issuance make headline net cash a poor equity-value shortcut.

Why a current target is withheld

A normalized earnings/cash-flow valuation cannot be converted into a reliable current share target without the post-split common, preferred conversion/warrant and ELOC/redemption bridge.

Downside and next tests

• PCCU accounted for 92.7% of H1 revenue; loss or change to this related-party relationship is material.
• SeriesB conversion/warrant resets, mandatory redemption use of ELOC proceeds and reverse-split denominator remain unresolved.
• Nasdaq October 20 extension is not restored compliance or assurance of continued listing.

• Full Q3 original accounts with completed reverse-split and preferred/ELOC share reconciliation.
• Verified Nasdaq compliance and dated post-action share count.

CIN model assumptions

• Runway holds H1 burn at 75%,100%,125%; diagnostic scenarios, not forecasts of Q3 or current October cash.
• No post-June share count or split-adjusted quote invented.

Model limits

• Complete current capital/redemption waterfall and compatible post-split quote are missing.
• Positive normalized recurring free cash flow not demonstrated; customer-deposit growth does not establish profit growth.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.

• Original filings show an early commercial rollout with very limited cash inflow, not an established recurring earnings franchise.
• Lower reported R&D loss versus prior year partly reflects the absence of a large noncash milestone-warrant charge; it is not a comparable improvement in product cash economics.
• October product/patent announcements are dated milestones; none supplies the volumes, pricing, gross margin and royalty burden needed for a defensible normalized cash-flow target.

Why a current target is withheld

Product milestones and a compatible quote do not establish a normalized cash-flow valuation. Original financial reconciliation, unit economics, royalty/lease claims and funding dilution remain incomplete.

Downside and next tests

• The marijuana test indicates recent use and does not measure impairment; DOT-like does not mean approved for federal DOT/SAMHSA testing.
• Material difference between stored financial figures and original MD&A plus internal MD&A date/revenue typos remains held pending original statement reconciliation.
• Cash runway is short on the historical burn; new equity, special warrants, options, royalties and leases can change per-share value materially.

• Original interim financial statements reconciling cash/lease balances, rollout revenue versus other income and prior-period figures.
• Contract volumes/prices, independently documented product economics, royalties and funded commercialization plan.

CIN model assumptions

• Cash sensitivity starts from July 31 balances, not an invented October cash balance.
• No revenue from headlines, regulatory clearance, granted patent, renewal or signed purchase quantity assumed.

Model limits

• No defensible normalized sales/gross-margin forecast or actual diluted current funding bridge.
• MDA and stored financial conflicts unresolved; no positive free cash-flow target qualified.

Selected original reported evidence

Original dates are retained. No provider installation, daily check or this publication renews an older observation. Unknown ownership and trading conflicts are not recorded as none.